Favorable outcomes of pregnancy with use of sibutramine in a woman with polycystic ovary syndrome: a case report

Yıl 2011, Cilt: 3 Sayı: 3, 36 - 38, 01.08.2011

Esra Sağlam Emine Nur Özdamar İ. Yaman Sağlam

Öz

Sibutramine is a drug used for long-term management of obesity. There is limited published data about sibutramine exposure during pregnancy. In this article, we present a 29-year-old, Caucasian woman with polycystic ovary syndrome who exposed to 15 mg/day of sibutramine during gestational weeks 1- 6 without knowing that she was pregnant. At 38th weeks, cesarean section was performed and a healthy male newborn weighted 4150 gram was born. We followed the infant for one year. No congenital abnormalities and developmental disorders were seen during this period. This report of the successful spontaneous pregnancy and favorable pregnancy outcomes following the use of sibutramine for obesity management in a woman with polycystic ovary syndrome may contribute to the limited knowledge about the exposure to this drug during pregnancy.

Anahtar Kelimeler

sibutramine, polycystic ovary syndrome, pregnancy, cesarean section, obesity

Polikistik over sendromu olan bir kadında sibutramin kullanımı ile olumlu gebelik sonuçları: bir olgu sunumu

Öz

Sibutramin şişmanlığın uzun vadeli tedavisi için kullanılan bir ilaçtır. Gebelikte sibutramine maruz kalma ile ilgili sınırlı sayıda yayınlanmış veri mevcuttur. Bu makalede, gebeolduğunun farkında olmadan 1-6. gebelik haftaları arasında 15 mg/gün sibutramine maruz kalan polikistik over sendromlu 29 yaşındaki Kafkas kökenli kadın olgu sunulmuştur. Gebeye 38. haftada sezaryen yapılmış ve 4150 gr ağırlığında sağlıklı erkek yeni doğan dünyaya gelmiştir. Bebek bir sene boyunca takip edilmiş ve bu süre içinde hiçbir konjenital anomali ya da gelişimsel bozukluğa rastlanmamıştır. Polikistik over sendromlu bir kadında,şişmanlık tedavisi için sibutraminin kullanımı sırasında başarılı spontan gebelik ve olumlu gebelik sonuçlarının sunumu, bu ilaca gebelikte maruziyetle ilgili sınırlı bilgiye katkıda bulunacaktır.

Anahtar Kelimeler

sibutramin, polikistik over sendromu, gebelik, sezaryen, şişmanlık

Kaynakça

• 1. James WPT.: The epidemiology of obesity: the size of the problem. J Intern Med 2008; 263: 336–352.
• 2. Haslam DW, James WPT.: Obesity. Lancet 2005; 366: 1197-1209.
• 3. Vrbikova J, Hainer V.: Obesity and polycystic ovary syndrome. Obesity Facts 2009;2: 26- 35.
• 4. Padwal RS, Majumdar SR.: Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 2007; 369: 71-77.
• 5. Tziomalos K, Krassas GE, Tzotzas T.: The use of sibutramine in the management of obesity and related disorders: An update. Vascular Health and Risk Management 2009;5: 441- 452.
• 6. Glazer G.: Long term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;161:1814- 1824.
• 7. Lindholm A, Bixo M, Bjorn I et al.: Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, doubleblind, plasebo-controlled trial. Fertil Steril 2008;89: 1221-1228.
• 8. Luque CA, Rey JA.: The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002;440:119-128.
• 9. Halford JCG, Harrold JA, Boyland EJ, Lawton CL, Blundell JE.: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67: 27- 55.
• 10. Halford JCG.: Pharmacotherapy for obesity. Appetite 2006;46:6-10.
• 11. Linne Y, Rossner S.: Pharmacotherapy of obesity. Clinics in Dermatology 2004;22: 319- 24.
• 12. Sachdeva P, Patel BG, Patel BK.: Drug use in pregnancy; a point to ponder. Indian J Pharm Sci. 2009; 71: 1–7.
• 13. Erkekoglu P, Giray B, Sahin G.: Toxicological evaluation of antiobesity drug use during pregnancy and lactation. Hacettepe Medical Journal 2008; 39: 121-133
• 14. Kadioglu M, Ulku C, Yaris F,et al.: Sibutramine use in pregnancy: report of two cases. Birth Defects Res A Clin Mol Teratol 2004;70:545-546.
• 15. Einarson A, Bonari L, Sarkar M, McKenna K, Koren G.:Exposure to sibutramine during pregnancy: a case series. Eur J Obstet Gynecol Reprod Biol 2004; 116: 112.
• 16. Ramzi F, Elias D, Mona S, Zreik TG.: Sibutramine in pregnancy. Eur J Obstet Gynecol Reprod Biol 2005;122:243-244.
• 17. De Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A.: Early first-trimester sibutramine exposure: pregnancy outcome and neonatal follow-up. Drug Safety 2006;29: 255-259.
• 18. Blank SK, McCartney CR, Marshall JC.: The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Human Reproduction Update 2006;12: 351–361.
• 19. Lobo RA, Granger LR, Paul WL, Goebelsmann U, Mishell DR Jr.: Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. Am J Obstet Gynecol 1983;145:496-503.
• 20. Rasgon NL, Rao RC, Hwang S, et al.: Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. Journal of Affective Disorders 2003;74: 299–304.
• 21. Apfelbaum ME.: Effect of serotonin on the basal and gonadotrophin- releasing hormone- induced release of luteinizing hormone from rat pituitary glands in vitro. Life Sciences 1987;41: 2069-76.
• 22. Smyte GA.: The role of serotonin and dopamine in hypothalamic-pituitary function. Clinical Endocrinology 1977; 7: 325-41.